ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
1,2,Application site pain,Application site reactions,Administration site reactions,Genrl,N
2,1,Chapped lips,Oral soft tissue disorders NEC,Oral soft tissue conditions,Gastr,N
2,2,Mouth swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
2,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
3,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
3,2,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
3,3,Rhinorrhoea,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
4,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
4,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
5,1,Skin swelling,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
6,1,Thermal burn,Thermal burns,Injuries by physical agents,Inj&P,N
7,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
